FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

or Section 30(h) of the Investment Company Act of 1940

W	as	hing	ton,	D.C.	2054	9

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average I	ourden								
-	hours por response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person* WAN MARK A						2. Issuer Name and Ticker or Trading Symbol ACELRX PHARMACEUTICALS INC							Relationship of Reporting Person(s) to Issuer (Check all applicable)						
WAN MAKK A					AC	ACRX]								X	Director			10% Ov	vner
(Last)	(Fi	rst)	(Middle)												Officer below)	(give title		Other (s	pecify
C/O ACELRX PHARMACEUTICALS, INC.								t Trans	action (Mo	nth/[Day/Year)								
351 GALVESTON DRIVE						06/25/2019													
(Street)					- 4. I	f Ame	endment,	Date o	of Original	Filed	(Month/Da	ay/Year)		6. Ind		oint/Group	Filing	(Check App	olicable
REDWO	OD	Λ.	04062											X	X Form filed by One Reporting Person				
CITY CA 94063															Form filed by More than One Reporting Person				
(City)	(Si	tate)	(Zip)																
		Tab	le I - No	n-Deriv	/ativ	e Se	curitie	s Ac	quired,	Dis	posed o	f, or B	enef	icially	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution Date,		Code (I	Transaction Disposed Of (D) (Instr. 5)					5. Amou Securitie Benefici Owned F Reported	ırities eficially ed Following		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount (A) or (D)		or F	Price	Transact (Instr. 3	tion(s)			(111511.4)
Common Stock ⁽¹⁾ 06/25/					5/201	9			A		3,750	(2) A		\$0.00	3,750			D	
		٦	Гаble II -								osed of, onvertil				Owned				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr		5. Number 6		6. Date Exercisable an Expiration Date (Month/Day/Year)		ble and			urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	Ov Fo Dii or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co	Code	v	(A)		Date Exercisable		Expiration Date	Title	or Nu of	mber ares					
Stock Option	\$2.19	06/25/2019			A		7,500		07/25/2019	(3)	06/25/2029	Commor	7.	500	\$0.00	7,500		D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- 2. The restricted stock units shall vest in two equal consecutive annual installments on June 25, 2020 and June 25, 2021, subject to Reporting Person's continuous service to the Company.
- 3. The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Reporting Person's continuous service to the Company.

Remarks:

(Right to

Buv)

/s/ Martha Adler, Attorney-In-

06/25/2019

Stock

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.